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Abstract
Background: Dysfunction of the retinal pigment epithelium (RPE) is implicated in numerous forms of retinal
degeneration. The readily accessible environment of the eye makes it particularly suitable for the transplantation of RPE
cells, which can now be derived from autologous induced pluripotent stem cells (iPSCs), to treat retinal degeneration.
For RPE transplantation to become feasible in the clinic, patient-specific somatic cells should be reprogrammed to
iPSCs without the introduction of reprogramming genes into the genome of the host cell, and then subsequently
differentiated into RPE cells that are well characterized for safety and functionality prior to transplantation.
Methods: We have reprogrammed human dermal fibroblasts to iPSCs using nonintegrating RNA, and differentiated
the iPSCs toward an RPE fate (iPSC-RPE), under Good Manufacturing Practice (GMP)-compatible conditions.
Results: Using highly sensitive assays for cell polarity, structure, organelle trafficking, and function, we found that
iPSC-RPE cells in culture exhibited key characteristics of native RPE. Importantly, we demonstrate for the first time with
any stem cell-derived RPE cell that live cells are able to support dynamic organelle transport. This highly sensitive test is
critical for RPE cells intended for transplantation, since defects in intracellular motility have been shown to promote
RPE pathogenesis akin to that found in macular degeneration. To test their capabilities for in-vivo transplantation, we
injected the iPSC-RPE cells into the subretinal space of a mouse model of retinal degeneration, and demonstrated that
the transplanted cells are capable of rescuing lost RPE function.
Conclusions: This report documents the successful generation, under GMP-compatible conditions, of human iPSC-RPE
cells that possess specific characteristics of healthy RPE. The report adds to a growing literature on the utility of human
iPSC-RPE cells for cell culture investigations on pathogenicity and for therapeutic transplantation, by corroborating
findings of others, and providing important new information on essential RPE cell biological properties.
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Background
The retinal pigment epithelium (RPE) is a monolayer of
cells that provides essential roles for the function and
viability of the photoreceptor cells [1]. Age-related
macular degeneration (AMD) is a widespread and com-
mon disease among older people, leading to irreversible
loss of central vision. The death of macular photorecep-
tors has been suggested to be secondary to the degener-
ation of the RPE [2–5]. Therefore, one promising form
of treatment for AMD is the transplantation of healthy
RPE cells into the retinas of human patients to restore
lost functions, and potentially halt or reverse the pro-
gression of the disease. Pluripotent stem cells, including
both human embryonic stem cells (ESCs) and human
induced pluripotent stem cells (iPSCs), can provide a
renewable source of human RPE cells, which are poten-
tially amenable for studying normal and disease mecha-
nisms in culture, and for intraocular transplantation for
disease treatment. Patient-derived iPSC-RPE cells offer
disease modeling and testing of pharmacologically active
compounds, in addition to autologous transplantation,
without the need for immunosuppression [6]. Originally,
iPSCs were generated by exogenous expression of the
factors described by Yamanaka’s group (OCT4, SOX2,
KLF4, and c-MYC) from retroviral vectors, thus result-
ing in genome integration [7]. To circumvent the risks
of genome integration, several nonintegrating methods
are now being used to induce pluripotency in mamma-
lian cells, including nonintegrating episomal vectors [8],
delivery of RNA [9] and proteins [10], and use of small
molecule compounds [11]. Once reprogrammed to plur-
ipotency, the iPSCs can spontaneously differentiate along
the neural lineage, and, further, to RPE cells, which are
readily discernible due to their pigmentation and cobble-
stone appearance [12, 13]. Several laboratories have now
published protocols for the differentiation of human
ESCs or iPSCs to RPE cells, using more directed ap-
proaches so as to increase the yield of RPE cells [14–17].
Taken together, the current technology allows for the
generation of patient-specific iPSCs that are free of inte-
grated reprogramming genes, and can subsequently be
used to generate the quantities of functional RPE cells
necessary for transplantation purposes.
This paper reports the use of a nonintegrating ap-
proach to generate iPSCs for the generation of RPE cells
under GMP-compatible practices. We have performed
in-vitro characterization of the iPSC-RPE cells to test
whether they express RPE-specific genes and proteins.
Importantly, we have also tested for the first time
whether RPE cells, derived from any type of stem cell,
possess normal cytoskeletal organization, organelle mo-
tility, and phagosome ingestion with degradation kinet-
ics, thus detailing critical cellular functions of the RPE in
relation to RPE dystrophy. The importance of these
tests, which includes live-cell imaging analysis, has been
emphasized by recent studies showing that defects in
intracellular motility lead to RPE pathogenesis like that
in AMD [18], potentially the most significant target dis-
ease of RPE transplantation. We have also tested these
iPSC-RPE cells in vivo, using mouse models, to deter-
mine whether the cells can integrate into a recipient tis-
sue, and rescue a function lost by the host retina. Our
results show that iPSCs, generated with a nonintegrating
method, can serve as a renewable source of functional
RPE cells, which can be used for detailed cell biological
analyses of pathogenicity in vitro, as well as for trans-
plantation in treatment of retinal diseases.
Methods
GMP facility
Fibroblast derivation, iPSC generation, and RPE differenti-
ation were performed in a GMP-compatible facility at the Eli
and Edythe Broad Center of Regenerative Medicine and
Stem Cell Research at UCLA– California Institute for Regen-
erative Medicine Shared Research Laboratories as described
previously [19]. All cells used in this study were handled by
qualified personnel. GMP-compatible protocols and proce-
dures were followed. The facility and equipment were rou-
tinely cleaned, calibrated, and monitored rigorously by
contract vendors. All materials used were qualified according
to the supplier certificate of analysis. Inventory records, and
generation and distribution of materials, were documented.
Derivation of fibroblasts
Pieces of skin biopsy (1 mm2) were incubated with 1 mg/ml
AOF Collagenase A (LS00415; Worthington Biochemical)
for 1 h. Released cells were washed twice and plated on
dishes, coated with CellStart™ (A1014201; Gibco), in Fibro-
gro™ medium (SCM037; EMD Millipore). Once confluent,
the cells were passaged using TrypLE™ Select (12563-011;
Invitrogen), and their purity was determined by the propor-
tion of cells expressing fibroblast cell markers. The cells
were stable in culture for at least five passages.
Generation and maintenance of iPSCs
The nonintegrating vector used for reprogramming of fi-
broblasts to iPSCs was the modified, noninfectious, self-
replicating Venezuelan Equine Encephalitis (VEE) virus
RNA replicon RNA system from EMD Millipore (catalog
number SCR550). This synthetic polycistronic RNA rep-
licon has all four reprogramming factors on a single
RNA strand, thereby eliminating the need to transfect
multiple individual mRNAs, and increasing the repro-
gramming efficiency over DNA-based and protein-based
reprogramming methods. Briefly, fibroblasts were trans-
fected with the vector, and selected with puromycin for
9–11 days in the presence of B18R protein (GF156;
EMD Millipore). Removal of the B18R protein mediates
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the elimination of the RNA replicon system from the
cultures. Selected cells were passaged onto Matrigel
(354277; BD) and allowed to grow for 3–4 weeks, during
which time iPSC colonies began to form. These colonies
were picked and passaged to establish individual iPSC
lines, which were subsequently maintained in culture
under feeder-free conditions, using a 1:1 formulation of
TeSR2 medium (05860; Stem Cell Technologies) and
NutriStem® medium (01-0005; Stemgent). A bioinfor-
matics assay for pluripotency, PluriTest, was performed
by Cedars-Sinai. Karyotyping was performed by Cell
Line Genetics.
Differentiation of iPSCs into RPE cells
RPE cells were differentiated from iPSCs, with modifica-
tions of a method described previously [14]. The iPSCs
were cultured for 2 weeks as embryoid bodies (EBs), sus-
pended in low-adherent dishes in basal medium, con-
taining Dulbecco’s Modified Eagle Medium: Nutrient
Mixture F-12 (DMEM/F12) (11330-032; Invitrogen),
supplemented with 14% xeno-free knockout serum
(12618-013; Invitrogen), 0.1 mM nonessential amino
acids (NEAA) (11140-050; Invitrogen), 2 mM Gluta-
Max™ (35050-061; Invitrogen), and 10 mM nicotinamide
(N0636; Sigma-Aldrich). The medium was changed
every other day. Growth factors including Activin A
(140 ng/ml, 120-14P; Peprotech), transforming growth
factor beta 1 (TGFB1) (2.5 ng/ml, AF-100-21C;
Peprotech), and fibroblast growth factor 2 (FGF2)
(20 ng/ml, 100-18B; Peprotech) were then added to the
basal medium, and the EBs were allowed to grow and
differentiate for an additional 2 weeks. The EBs were
then returned to basal medium until pigmentation be-
came evident. The pigmented regions in the EBs were
separated by scalpel dissection, and plated as adherent
cultures in RPE medium: DMEM/F12 with 5% fetal
bovine serum (FBS) (FB-12; Omega Scientific), 4%
normal human AB serum (IPLA-SERAB-HI; Innovative
Research), triiodothyronine (0.02 ng/ml, T6397; Sigma-
Aldrich), hydrocortisone (0.02 μg/ml, H0888; Sigma-
Aldrich), taurine (0.25 mg/ml, T0625; Sigma-Aldrich),
10 mM nicotinamide, 0.1 mM NEAA, 1× N1
(N6530; Sigma-Aldrich), 1 × B27 (A14867-01; Invitrogen),
0.1 mM β-mercaptoethanol (M3148; Sigma-Aldrich), and
GlutaMax™. Pigmented cells were passaged, following gen-
tle collection with medium after 5-min TrypLE™ treat-
ment. For the following analyses, RPE cells were cultured
in RPE medium (as earlier, but lacking B27 and β-
mercaptoethanol, and containing MEM alpha (32561-037;
Invitrogen) with 1% FBS), at 37 °C and in 5% CO2. For all
experiments, iPSC-RPE cells were passaged one to four
times beyond their derivation from the pigmented EBs,
and unless otherwise stated the results in the figures were
obtained from iPSC-RPE line 2.
Immunocytochemistry
iPSC-RPE cells were seeded (1.66 × 105 cm–2) on Transwell
inserts (3470; Corning) or 12-mm glass coverslips, coated
with laminin (23017015; Thermo Fisher), and cultured for
6–8 weeks. Cultures were washed twice with phosphate-
buffered saline (PBS), fixed with 4% formaldehyde in PBS
for 10 min, washed with PBS, permeabilized with 0.25%
Triton X-100, and then blocked with 4% bovine serum al-
bumin (BSA) or 10% normal goat serum (NGS) (50-062Z;
Invitrogen) in PBS for 1 h. They were immunolabeled for
1 h at room temperature in PBS, containing 1% BSA or
10% NGS, and antibodies against the following proteins:
SOX2 (sc-17320; Santa Cruz Biotechnology), NANOG
(AB9220; EMD Millipore), OCT4 (#2840; Cell Signaling
Technology), fibroblast-specific protein-1 (FSP-1) (ABF32;
EMD Millipore), vimentin (ab92547; Abcam), RPE65
(ab67042; Abcam), microphthalmia-associated transcrip-
tion factor (MITF) (ab20663; Abcam), bestrophin 1
(BEST1) (ab2182; Abcam), zona occludens-1 (ZO-1)
(40-2200; Life Technology), occludin (ab31721; Abcam),
claudin19 (H00149461-M02; Novus Biologicals), rhodopsin
(RHO) (RHO pAb01 [20, 21]), integrin αVβ5 (ab24694;
Abcam), and MER proto-oncogene, tyrosine kinase
(MERTK) (NB110-57199; Novus Biologicals). Following
primary antibody incubation, cultures were washed 3 ×
5 min, and incubated with Alexa Fluor-conjugated second-
ary antibodies (Invitrogen) for 1 h at room temperature, in
the dark. Cultures were washed 3 × 5 min with PBS.
Membranes of Transwell inserts were excised and
mounted onto frosted microscope slides using Fluoro-Gel
II mounting medium with 4,6′-diamino-2-phenylindole
(DAPI) (17985-50; Electron Microscopy Sciences) to coun-
terstain the nuclei. Images were acquired with an Olympus
FluoView 1000 confocal microscope or a Zeiss Axiovert
200 M microscope.
Phagocytosis of photoreceptor outer segments
Porcine eyes were obtained from a local slaughterhouse
for the purification of photoreceptor outer segments
(POSs), following a method used previously for bovine
POS purification [22]. Briefly, retinas were isolated and
homogenized under dim red light. The homogenate was
then loaded onto a continuous (27–50%) sucrose gradi-
ent to purify the POSs, which contain outer segments
from rods (ROSs) and cones (COSs). The POSs were
frozen in DMEM with 2.5% sucrose at – 80 °C. For
phagocytosis assays, the POSs were thawed at room
temperature and incubated with iPSC-RPE cells on
laminin-coated Transwell inserts (10 POSs/cell) for 2 h.
After the POS challenge, cells were washed with PBS,
containing 0.9 mM calcium and 0.49 mM magnesium
(PBS-CM), and immediately processed for immunofluor-
escence (pulse), or incubated further before processing
for immunofluorescence (chase).
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A double immunofluorescence labeling strategy, using
an antibody against RHO, was used to distinguish be-
tween ROSs bound to the surface of the iPSC-RPE cells
and ROSs that have been internalized, as described pre-
viously [23, 24]. Briefly, cultures were fixed with 4% for-
maldehyde for 10 min, and blocked with 1% BSA in
PBS-CM for 15 min. Surface-bound ROSs were labeled
with the RHO pAb01, followed by an Alexa Fluor 488-
nm-conjugated goat anti-rabbit secondary antibody.
After permeabilization with 50% ethanol in PBS-CM for
5 min, all ROSs were labeled with the same RHO anti-
body, followed by an Alexa Fluor 594-nm-conjugated
goat anti-rabbit secondary antibody. Finally, cells were
washed with DPBS-CM before the membranes of the
Transwell inserts were excised and mounted onto mi-
croscopy slides. Confocal Z-stacks of randomly selected
fields of view were acquired on an Olympus confocal
microscope using a 60× NA1.4 oil objective. Surface-
bound ROSs were labeled with both secondary anti-
bodies, thereby appearing yellow. Internalized ROSs
were labeled only with the Alexa Fluor 594-nm-
conjugated secondary antibody, and therefore appeared
red. For quantification, ROSs with a minimum diameter
of 0.5 μm were counted from a total of six to eight fields
of view using imageJ software. Analysis of ROS degrad-
ation was performed by comparing the total number of
ROSs after the 2-h pulse with the number after 2-h and
5-h chase periods.
Live-cell imaging
iPSC-RPE cells were plated on laminin-coated Lab-Tek™
chambered coverglass (155411; Fisher Scientific), and
allowed to polarize for 8 weeks. To label acidic organ-
elles, including endolysosomes, the cells were incubated
with RPE medium containing 100 nM LysoTracker Red
DND-99 (L7528; Thermo Scientific) for 1 h at 37 °C.
After washing to remove excess dye, fresh medium con-
taining 25 mM HEPES (15630-080; Gibco) was added to
the cells. Live-cell imaging was performed using an
Ultraview ERS spinning disk with a Zeiss Axio Observer
microscope, and an environmental chamber maintained
at 37 °C. Movies were acquired with a 63× oil objective
at 1.9 frames per second, using Volocity (PerkinElmer).
The trajectories of labeled organelles were analyzed in
the x and y dimensions, during a time period of 20–40 s,
using Volocity and Imaris × 64 (Bitplane) software.
Transepithelial resistance measurements
Transepithelial resistance (TER) was measured for iPSC-
RPE cells cultured on laminin-coated Transwell inserts
(growth surface area, 0.33 cm2), using an EVOM2
Epithelial Voltohmmeter (World Precision Instruments)
with a STX2 electrode. Measurements were made within
3 min of removal from the incubator. The net TER was
determined by subtracting the resistance across a
laminin-coated Transwell insert, lacking cells, from mea-
sured values, and then multiplying by the surface area.
RNA preparation and expression analysis
Total RNA from the iPSC-derived RPE was extracted
using the RNeasy Mini Kit (74104; Qiagen). RNA con-
centrations were measured using a Qubit fluorometer.
Single-strand cDNA was synthesized from 200 ng of
total RNA, using Superscript IV and random hexamer
primers (N8080127; Fisher Scientific) in a volume of 20
μl. The cDNA was used for semi-quantitative reverse
transcription-polymerase chain reaction (RT-PCR) ana-
lysis. PCR reactions were performed using GoTaq® Flexi
DNA polymerase (M829; Promega). Thermal cycling
conditions were performed as follows: one cycle at 94 °C
for 300 s; 30 cycles at 94 °C for 30 s, 60 °C for 30 s, and
72 °C for 30 s; and one cycle at 72 °C for 300 s. The
sequences of primers used for the PCR include: RPE65,
5′-TCCCCAATACAACTGCCACT-3′ and 5′-CCTTG
GCATTCAGAATCAGG-3′; MERTK, 5′-TCCTTGGCC
ATCAGAAAAAG-3′ and 5′-CATTTGGGTGGCTGAA
GTCT-3′; BEST1, 5′-TAGAACCATCAGCGCCGTC-3′
and 5′-TGAGTGTAGTGTGTATGTTGG-3′; and GAP
DH, 5′-ACCACAGTCCATGCCATCAC-3′ and 5′-TCC
ACCACCCTGTTGCTGTA-3′ [25].
Western blot analyses
Cells were lysed in RIPA-I lysis buffer (89900; Fisher
Scientific) with added protease inhibitor cocktail
(11836153001; Roche). Protein concentrations were
estimated using a Qubit fluorometer (~30 μg protein
was applied to each lane). Proteins were transferred to
Immobilon PVDF membranes (IPVH00010; EMD
Millipore), which were blocked with TBS with 0.05%
Tween 20 (P9416; Sigma-Aldrich) and 5% skimmed milk
for 30 min, and then probed with anti-RPE65. HRP-
conjugated secondary antibodies were visualized by en-
hanced chemiluminescence (RPN2232; GE-Healthcare).
Subretinal injections
iPSC-RPE cells were injected into the subretinal space of
Mertk–/– mice (129 genetic background) and BALB/cJ
albino mice. Cultures of iPSC-RPE cells were washed
thoroughly with PBS before enzymatic dissociation with
TrypLE™. BSS PLUS™ (0065080050; Alcon Laboratories)
was added to create a suspension at a concentration of
50,000 cells/μl. Mice (postnatal day (P) 10–16) were
anesthetized by isoflurane inhalation. Their pupils were
dilated with a drop of 1% (w/v) Atropine Sulfate ophthal-
mic solution (17478-215-02; Akorn Pharmaceuticals), and
the corneas were kept moist with Hypromellose ophthal-
mic demulcent 2.5% solution (51394-315-15; Wilson
Ophthalmic Corp.). A 1-μl suspension of iPSC-RPE cells
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was injected into the subretinal space of each eye, under a
Zeiss Stemi 2000 microscope, as described previously [26].
Ophthalmic ointment (Neomycin & Polymyxin B sulfates
and Dexamethasone, 61314-631-36; Falcon Pharmaceuti-
cals) was applied to each eye immediately following injec-
tion. Cyclosporine (200 mg/l, 0078-0109-61; Novartis) was
added to the drinking water of the dam from 1 day prior
to the injection until the pups were weaned at P28. Mice
were kept on a 12-h dark/12-h light cycle. For experi-
ments concerning phagosomes, they were killed between
15 and 30 min after lights on.
Microscopy
For fluorescence microscopy, eyes were fixed, embedded
in OCT, cryosectioned, and immunolabeled as described
previously [18]. Semi-thin sections were prepared for
light microscopy by fixation and Epon embedment, as
described previously [18].
Statistical test
GraphPad Prism 7 and Microsoft Excel were used to per-
form statistical analyses. The data were represented by the
mean ± the standard deviation or standard error of the
mean. A two-tailed Student t test was used to determine
whether there was a significant difference in photorecep-
tor nuclei counts between control vs iPSC-RPE-injected
eyes. p ≤ 0.05 was considered statistically significant.
Results
RNA-based reprogramming of fibroblasts into iPSCs
Mechanical (i.e., scalpel) and enzymatic (i.e., collagenase)
methods were used to isolate fibroblasts from human
dermal tissue obtained via skin biopsy. The identity of
fibroblasts was confirmed by immunolabeling for FSP-1
(Fig. 1a) and for vimentin (Fig. 1b). Immunolabeling re-
vealed that ≥ 95% of the cells expressed both FSP-1 and
vimentin. The fibroblasts could be cultured and propa-
gated using xeno-free conditions; they remained stable
in culture for at least five passages. To generate iPSCs,
using a nonintegrating method, we transfected the fibro-
blasts with the VEE RNA vector [27], which induces ex-
ogenous expression of pluripotency markers, including
OCT4, KLF4, SOX2, and GLIS1. Following puromycin
selection, cells were replated and cultured on Matrigel
for 3–4 weeks, when the formation of iPSC colonies was
evident. The identity of iPSCs was confirmed by immu-
nolabeling for pluripotency markers, including NANOG,
SOX2, and OCT4 (Fig. 1c–e). Normal karyotype was
shown by G-banding (Fig. 1f ). Additionally, the iPSCs
were capable of generating cells from all three embry-
onic germ layers in a bioinformatics assay for pluripo-
tency, PluriTest (Fig. 1g).
Differentiation and characterization of iPSC-RPE cells
To derive RPE cells, colonies of iPSCs (Fig. 2a) were
transferred as suspension cultures in low-adherent
dishes to generate EBs (Fig. 2b). After 2 weeks in cul-
ture, Activin A, TGFB1, and FGF2 were added to the
medium for a period of 2 weeks. Following the removal
of these growth factors, we observed the appearance of
pigmented EBs in as early as 4 weeks (Fig. 2c). The pig-
mented regions (Fig. 2d) of the EBs were dissected and
plated as adherent cultures in RPE medium. The pig-
mented regions adhered as a large mass from which pig-
mented cells began to proliferate and migrate near the
periphery (Fig. 2e). The pigmented cells were enzymati-
cally passaged and cultured until confluent monolayers
of pigmented cells with cobblestone morphology ap-
peared (Fig. 2f; Additional file 1A, B). Pigmented cells
were derived from three individual iPSC lines, which, by
western blotting analysis, were confirmed to express the
RPE-specific protein, RPE65 (Fig. 3a). Additionally, after
2–3 months in culture, RPE cells from multiple iPSC
lines showed robust expression of RPE genes, including
RPE65, MERTK, and BEST1, by semi-quantitative RT-PCR
(Fig. 3b). By immunocytochemistry, these pigmented cells
showed expression of RPE signature proteins, such as
BEST1, RPE65, and MITF (Fig. 3c–e), and no detectable
expression of the pluripotency marker OCT4 (Fig. 3f).
Taken together, these results indicate that the pigmented
cuboidal cells derived from our integration-free iPSCs have
expression characteristics of RPE cells.
Phagocytosis of photoreceptor outer segments by
iPSC-RPE cells
One of the primary functions of the RPE is the phago-
cytosis of distal tips of POS disk membranes [28].
Defects in this process have been shown to cause photo-
receptor degeneration [29], with defects in the degrad-
ation phase linked to RPE pathogenesis [18, 30]. The
initial process of phagocytosis by the RPE involves
binding followed by ingestion of POS membranes, two
events in which integrin αVβ5 and MERTK receptors
have been shown to participate, respectively [31, 32].
While RPE cells derived from stem cells have been
shown to phagocytose POS membranes previously [33],
here we have explored this function more extensively.
We first tested whether our iPSC-RPE cells expressed
these receptors at their surface. Immunocytochemistry
confirmed the expression of integrin αVβ5 (Fig. 4a) and
MERTK (Fig. 4b), which colocalized at the surface of the
iPSC-RPE cells (Fig. 4c). To test the phagocytic function
in our iPSC-RPE cells, we cultured the cells on laminin-
coated Transwell inserts, and challenged them with por-
cine POSs for 2 h to allow sufficient time for binding
and ingestion to occur. Following the challenge, and
after extensive washes to remove unbound POSs, some
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Fig. 1 Reprogramming of human fibroblasts into induced pluripotent stem cells. a, b Fibroblast cells immunolabeled with antibodies against
FSP-1 (a, green) or vimentin (b, red). DAPI (blue) was used to counterstain the nuclei. c–e iPSCs immunolabeled with antibodies against NANOG
(c), SOX2 (d), and OCT4 (e). Expression of these proteins indicates the identity of iPSCs derived from fibroblast reprogramming. f Normal karyotype of an
iPSC line determined by G-banding. g Results from PluriTest assay show that our iPSCs have a pluripotent signature (high pluripotency score and low
novelty score), and cluster with well-characterized bona-fide iPSC and ESC lines (red background hint; iPSC line 2 is indicated by a yellow arrowhead in
the magnified panel) and not with partially differentiated pluripotent cells or somatic tissue (blue background hint). Scale bars: a, b, 50 μm; c–e, 20 μm.
FSP-1 fibroblast-specific protein-1
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cultures were allowed additional time (2 or 5 h) to de-
grade the POSs they had ingested. Using a double
immunolabeling strategy for RHO, a protein abundant
in the ROSs but not expressed by the RPE (Fig. 4d), we
first labeled ROSs bound to the surface of the RPE cells
(Fig. 4e), and then, after permeabilization of the cells, la-
beled all ROSs (bound and ingested) (Fig. 4f ). Thus, we
were able to discriminate between bound and ingested
ROSs (Fig. 4g). We found that when the iPSC-RPE cells
were cultured on laminin-coated Transwell inserts (to
achieve a polarized monolayer of cells), approximately
60% of the ROSs were bound to the surface of the cells
while approximately 40% had been internalized at the
end of a 2-h challenge (Fig. 4h). When given additional
time (chase) after the POS challenge, the iPSC-RPE cells
were able to degrade more than 50% of the total ROS
phagosomes during a 5-h chase period (Fig. 4i,
Additional file 2). These results demonstrate that GMP-
compatible iPSC-RPE cells are capable of binding, in-
ternalizing, and subsequently degrading ROSs. The rate
of ROS phagosome degradation was much faster than
that reported for human RPE cells from immortalized
cell lines; no significant degradation of opsin was de-
tected in human d407 cells until more than 8 h after the
removal of unbound POSs [34].
Organelle trafficking in live iPSC-RPE cells
Normal trafficking of organelles is essential for the func-
tion of RPE cells [35], and is a sensitive measure of the
polarized organization of their cytoskeleton, as well as
their metabolic health. In particular, the process of POS
phagocytosis relies on the trafficking of POS-derived
phagosomes, and their interaction with degradative
organelles such as endolysosomes for POS clearance
[36, 37]. When this trafficking is perturbed, RPE health be-
comes compromised, with the development of AMD-like
pathogenesis [18, 38]. Prior to examining organelle traffick-
ing in our iPSC-RPE cultures, we used immunofluores-
cence confocal microscopy to evaluate the organization of
the microtubules. This organization is a sensitive indicator
of epithelial cell polarization. In addition, the microtubules
serve as essential cytoskeletal elements for trafficking POS
phagosomes and endolysosomes in the RPE [18, 39].
Transverse sections of alpha tubulin immunolabeling, at
different depths in the cell body (Fig. 5a; Additional file 3),
show microtubules that in the apical region extended into
the plane of the section, indicating a horizontal orienta-
tion, and in the basal region appeared more punctate,
indicating a vertical orientation, most concentrated
adjacent to the plasma membrane. Additionally, the stain-
ing revealed primary cilia, indicated by white arrowheads
in z-plane views under Fig. 5a, emanating from the apical
surface of the iPSC-RPE cells. This organization of micro-
tubules is consistent with that observed in other polarized
epithelial cells [40–43]. To evaluate the trafficking of or-
ganelles in our iPSC-RPE cultures, we incubated the cells
with LysoTracker, which labels acidic organelles such as
endosomes and lysosomes, and used high-speed spinning
disk confocal microscopy to perform live-cell imaging
(Fig. 5b; Additional file 4). Following movie acquisition,
the tracks of labeled organelles were analyzed during a
time interval of 20–40 s (Fig. 5c). We found that the
average speed of labeled organelles ranged from 0.2 to
0.5 μm/s, and this range was similar among RPE cells de-
rived from the three independent iPSC lines (Fig. 5d).
Similar speeds have been observed for LAMP2-positive
Fig. 2 Differentiation of iPSCs into RPE cells. The differentiation process begins with colonies of iPSCs plated initially on Matrigel (a) and
subsequently detached to be cultured as EBs in suspension, and in the presence of NIC for 2 weeks (b). c, d The EBs became pigmented
following a 2-week exposure to Activin A, TGFB1, and FGF2. The pigmented regions in the EBs were mechanically dissected and plated in RPE
medium (e) giving rise to a monolayer of pigmented cells with a cobblestone appearance that can be further purified and expanded (f). Scale
bars: a, b, 20 μm; c, 50 μm; d, 10 μm; e, 100 μm; f, 50 μm
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organelles in polarized primary cultures of porcine RPE
[44], and they represent a range consistent with micro-
tubule transport. Interestingly, many of these labeled or-
ganelles can be seen moving in and out of the x–y plane,
suggesting vertical motility along the z axis (Fig. 5e), con-
sistent with the presence of vertical microtubules, which
are a hallmark of well-polarized epithelial cells.
Transepithelial resistance
The RPE is situated between the photoreceptors and the
choriocapillaris, thereby serving as a blood–retinal
barrier [45]. To perform such a function, the RPE forms
tight junctions near its apical surface to tightly regulate
the flux of ions, molecules, and fluid between the inner
retina and the blood supply [46]. To test whether our
iPSC-RPE cells expressed the proteins necessary to form
these tight junctions, we cultured the cells on laminin-
coated Transwell inserts and performed immunocyto-
chemistry to examine the expression of tight junction
proteins, including ZO-1, occludin, and claudin19. The
immunostaining revealed that the cells, which have
proper cortical arrangement of actin filaments (Fig. 6a;
Fig. 3 Specific protein and gene expression profiling of iPSC-derived RPE cells. a Expression of RPE65 by 2.5–3-month cultures of RPE cells from
three different iPSC lines, indicated by an immunolabeled western blot image. Actin was used as a loading control. b Expression of RPE65, MERTK,
and BEST1 genes in iPSC-RPE cells cultured for 2–3 months, detected by RT-PCR. GAPDH was used as a loading control. c–e Expression of the
RPE-specific proteins BEST1 (c), RPE65 (d), and MITF (e), indicated by immunofluorescence. f iPSC-RPE cells showed no expression of the pluripotency
marker OCT4; nuclei labeled with DAPI. Scale bars: c, 20 μm; d, e, 50 μm; f, 20 μm. HEK human embryonic kidney cells, iPSC induced pluripotent stem cell,
RPE retinal pigment epithelium, MERTK MER proto-oncogene, tyrosine kinase, BEST1 bestrophin 1, GAPDH glyceraldehyde-3-phosphate dehydrogenase,
MITF microphthalmia-associated transcription factor
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Additional file 1C, D), expressed the three tight junction
proteins, with normal localization at the plasma mem-
brane (Fig. 6b–d; Additional file 1E–H).
The resistance across the RPE layer provides a meas-
ure of the function of the tight junctions. To measure
the TER, we cultured our iPSC-RPE cells on laminin-
Fig. 4 Phagocytosis of photoreceptor outer segments by iPSC-RPE cells in vitro. Immunofluorescence labeling of iPSC-RPE cells for integrin αvβ5
(a) and MERTK (b). These receptors are responsible for the binding and internalization of POSs, respectively, and are present on the apical surface.
c Image merge of a and b. The ability of iPSC-RPE cells to phagocytize POSs was tested in vitro by challenging the cells with POSs isolated from
porcine retinas. d Micrograph of iPSC-RPE cells that have not been exposed to POSs and labeled with RHO antibody. Nuclei counterstained with
DAPI. e Representative image of bound ROSs, labeled with an antibody against RHO and a green secondary antibody, prior to cell permeabilization.
f Representative image of all (internalized and bound) ROSs labeled with the same RHO antibody, but with a red secondary antibody, following cell
permeabilization. g When merged, the surface-bound ROSs appear yellow while internalized ROSs appear red. A few internalized ROSs are indicated
by white arrowheads. h Quantification of bound and ingested ROSs was performed using the ImageJ software to count RHO-positive particles with
diameters greater than 0.5 μm. i Total ROSs per field of view were quantified after the 2-h pulse, and after a 2-h and 5-h chase. Phagosome counts
were obtained from six to eight individual fields of view, with each field containing ≥ 100 cells. h, i Data represent mean ± SD. Scale bars: a, d, 20 μm;
e–g, 5 μm. ROS rod outer segment
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Fig. 5 (See legend on next page.)
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coated Transwell inserts, and made recordings at 2-week
intervals. We observed a steady increase in the TER until
it reached a maximal level of slightly above 200Ω.cm2,
by 8 weeks of culture (Fig. 6e). This value is consistent
with the reported net TER of human RPE in vivo, which
ranges from 150 to 200Ω.cm2 [47–49]. Collectively, the
expression of tight junction proteins and the measured
TER indicate that the iPSC-RPE cells are capable of
establishing an appropriate epithelial barrier in vitro.
Integration of human iPSC-RPE into the murine RPE
in vivo
Transplantation of healthy and functional RPE cells has
the potential of treating an eye with diseased or dysfunc-
tional RPE. To test for integration of iPSC-RPE cells into
an RPE layer in vivo, we injected suspensions of RPE
cells into the subretinal space of albino mouse eyes
(Fig. 7a). After various intervals, retinal cryosections
were obtained and fluorescently labeled with RHO anti-
bodies and phalloidin for f-actin. Images of phase con-
trast merged with RHO and actin fluorescence revealed
that the injected pigmented iPSC-RPE cells, delineated
by the phalloidin labeling for actin, had integrated into
the host retina, and were situated apical to the outer
segments of the photoreceptors, marked by the RHO
labeling (Fig. 7b–e). Additionally, the pigmented iPSC-
RPE cells also contained phagosomes, derived from
ingested ROSs, suggesting that the integrated cells were
capable of performing phagocytosis (Fig. 7b).
Light microscopy on semi-thin sections from injected
eyes confirmed the presence of melanosome-containing
cells that were absent in noninjected eyes (Fig. 7f, g).
Following the longest interval post injection that we
tested, 205 days, these pigmented cells remained detect-
able in the retinas of injected albino eyes (Fig. 7h). It is
important to note that the melanosomes were evident in
the apical processes of the RPE cells, in addition to the
cell body (Fig. 7g, red arrows). Localization to the apical
processes, and with an orientation that is approximately
parallel to that of the POSs, has been shown to require
the molecular motor, myosin-7a, in mouse [50, 51] and
human [52] RPE, and demonstrates that the melano-
somes are endogenous to the RPE cells. An alternative
explanation for the presence of melanosomes in the RPE
is that albino host cells ingested debris from the injected
pigmented cells. While such ingestion can happen, it re-
sults in the retention of the melanosomes only within
vacuoles in the RPE [26]. These results confirm that a
suspension of iPSC-RPE cells can be targeted to the
outer retina, where the cells are capable of integrating
into the host tissue, and can remain stable for a signifi-
cant period of time after the injection procedure.
In-vivo rescue of retinal degeneration by iPSC-RPE cells
RPE dysfunction or pathology has been indicated in nu-
merous forms of retinal degeneration, including retinitis
pigmentosa, Best disease, Stargardt’s disease, and AMD.
It is therefore appealing to use iPSC-derived RPE for au-
tologous transplantations to rescue RPE functions lost in
some of these degenerative diseases. In our in-vivo stud-
ies, we used the Mertk–/– mouse as a model of retinal
degeneration, with RPE dysfunction, and tested whether
our iPSC-RPE cells could rescue the inherent phagocyt-
osis deficiency of the RPE.
We injected suspensions of 50,000 iPSC-RPE cells into
the subretinal space of Mertk–/– mice at age P10, long
before retinal degeneration has been observed to occur
in this model. The animals were sacrificed 27 days post
injection, and thick cryosections and semi-thin Epon
sections were obtained from the retinas. The cryosec-
tions were stained with phalloidin to identify the apical
region of the RPE, and an antibody against RHO to
identify phagosomes of ROSs phagocytized by the RPE.
In the semi-thin sections, phagosomes were identified by
heavy staining with toluidine blue. MERTK functions in
the ingestion of POSs by the RPE, so that the Mertk–/–
RPE lacks phagosomes [53], and the presence of numer-
ous phagosomes in the RPE layer is an indicator of
transplanted functional iPSC-RPE. Figure 7i shows
phagosomes that have been identified by RHO immuno-
labeling. Figure 7j shows a cluster of toluidine blue-
stained phagosomes (yellow arrows) in a semi-thin
(See figure on previous page.)
Fig. 5 Microtubule organization and trafficking of endolysosomes in iPSC-RPE cells. a Microtubule organization in the iPSC-RPE cell bodies illustrated
by immunostaining of alpha tubulin. Single-plane confocal microscopy images (2-μm apart) represent the apical and basal regions of the cell bodies,
plus one plane in between (middle). The apical region of the cells is dominated by horizontal microtubules while the basal region is dominated by
vertical microtubules. A z projection of the three panels is shown in the fourth panel. Below are images in two z planes at the yellow lines in the
z-projection image, showing primary cilia (indicated by white arrowheads) emanating from the apical surface of the RPE cells. b Still image from a
movie of iPSC-RPE cells that were incubated with red LysoTracker to label endolysosomes (see Additional file 4 for a similar movie). c Trajectory and
movement analysis of a population of endolysosomes, using a spots and tracks analysis (Imaris), following movie acquisition over a 25-s interval. The
tracks represent the trajectories of the organelles, while their colors are indicative of how far (in terms of time) they are with respect to the 25-s movie,
with cool colors being closer to the beginning of the movie, and hot colors being closer to the end of the movie. d Time-lapse images from a movie
showing vertical movement of a labeled organelle (yellow arrowhead). Each panel represents the same z plane at different times. The organelle moves
out of the plane after 2 s, indicating that it is traversing different z planes. Scale bars: a, b, 20 μm; c, 25 s (time), 5 μm (distance); e, 5 μm. iPSC induced
pluripotent stem cell, RPE retinal pigment epithelium
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Fig. 6 Tight junction proteins and the transepithelial resistance of iPSC-RPE. RPE cells were cultured on laminin-coated Transwell inserts. a Phalloidin
labeling demonstrates the cortical arrangement of actin filaments in iPSC-RPE. b–d Immunostaining of the iPSC-RPE cells revealed surface expression
of the tight junction proteins ZO-1 (b), occludin (c), and claudin19 (d). e To assess the barrier function of the iPSC-RPE cells, the resistance across
monolayers of cells cultured on laminin-coated Transwell inserts was measured at 2-week intervals, following initiation of the cultures. The net TER
was determined by subtracting the resistance across a laminin-coated Transwell insert lacking cells, and multiplying by the surface area of the insert
(0.33 cm2). The net TER of the iPSC-RPE cells steadily increased between weeks 2 and 8, until it reached a maximal value of just above 200Ω.cm2.
Resistance recordings were made from four individual cultures. e Error bars represent the mean ± the SEM. Scale bars: a–d = 20 μm. ZO-1 zonula
occludens-1, TER transepithelial resistance
Hazim et al. Stem Cell Research & Therapy  (2017) 8:217 Page 12 of 17
Fig. 7 Transplantation of human iPSC-RPE cells into murine eyes. a–h Injection of pigmented human iPSC-RPE cells into the subretinal space of
albino mouse eyes. In the examples illustrated, injections were performed at P14. a Posterior segment of a whole eye, 28 days after injection,
showing evidence of pigment. b–d Thick retinal cryosection, 28 days after injection, labeled with anti-RHO (b) and phalloidin (c), shown under
phase contrast (d). e Merge of RHO and actin labeling, together with phase contrast imaging. RHO labels ROSs, as well as phagosomes in the RPE
(yellow arrows in b; inner retina is lower left). Phalloidin labeling of f-actin delineates the apical RPE. Pigmentation in the RPE cells is evident by the
phase-contrast imaging. Pigmented RPE cells are therefore evident in the RPE layer, adjacent to the labeled ROSs, and contain ROS phagosomes.
f–h Retinal semi-thin sections from a P40 noninjected albino mouse (control) (f), and from albino mice fixed 28 days (g) or 205 days (h) after injection.
Boxed regions in the lower panels are shown at higher magnification in the upper panels. iPSC-RPE cells are identifiable by the presence of melanosomes
in the apical processes (red arrows in g), adjacent to the tips of the POSs, in addition to the cell body. Pigmented iPSC-RPE cells (red arrows in h) remain
integrated in the retina, 200 days post injection. i–k Injection of pigmented human iPSC-RPE cells into the subretinal space of Mertk–/– mouse eyes. In
the examples illustrated, injections were performed at P10, and retinas were examined 27 days after injection, at P37. i Fluorescence micrograph of
retinal section labeled with anti-RHO (green) and phalloidin (red). Nuclei were counterstained with DAPI. Yellow arrows in an enlarged region (upper)
indicate RHO-positive phagosomes in transplanted iPSC-RPE cells. j Micrograph of toluidine blue-stained semi-thin section (yellow arrows indicate ROS
phagosomes). k Quantification of photoreceptor nuclei in semi-thin sections of the central retina. For the data illustrated, injections were made with PBS
(control) or iPSC-RPE cells (p= 0.0001) at P10, and sections were obtained 27 days later, at P37. For reference, the central region of a 1–2-month-old WT
retina contains ~ 10 rows of photoreceptor nuclei (e.g., f). Scale bars: b–e, 5 μm; f–h, 20 μm; i, j, 10 μm. iPSC induced pluripotent stem cell, ONL outer
nuclear layer, POS photoreceptor (rod and cone) outer segment, RHO rhodopsin, RPE retinal pigment epithelium
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section of the RPE layer. The semi-thin sections were also
used to quantify the number of rows of photoreceptor nu-
clei in the outer nuclear layer (ONL) of the central retina,
near the injection site. This quantification showed that
Mertk–/– mice injected with iPSC-RPE cells had more
rows of nuclei in the ONL, relative to noninjected mice
(Fig. 7k). Overall, these results demonstrate the ability of
iPSC-RPE to rescue a lost function of the RPE, in vivo,
and partial rescue of photoreceptor degeneration, in a
mouse model of inherited retinal degeneration.
Discussion
Numerous in-vitro cell models have been used to study
basic human RPE cell biology, including primary cultures
from donor tissues, and immortalized cell lines, such as
ARPE-19, d407, and hTERT-RPE1 [54, 55]. Although RPE
cultures from human fetal tissue do mimic in-vivo charac-
teristics well [56, 57], their supply is limited, and a large
supply of isogenic cell cultures is not feasible. On the
other hand, RPE cultures from immortalized cell lines
have been reported to fall short of in-vivo characteristics,
including signature gene expression, robust TER, struc-
tural polarity, and functional aspects such as kinetics of
POS phagosome degradation [34, 58–60]. Many of these
limitations have been mitigated by using human pluripo-
tent stem cells to obtain RPE cells in large quantities for
cell culture studies as well as therapeutic transplantation.
Here, we have advanced the use of iPSC-RPE cells by a
GMP-compatible method of iPSC generation, coupled
with novel analyses of critical cell biological functions.
RPE cells were one of the first cell types to be isolated
from pluripotent stem cells, due to their readily discernible
pigmentation [12], and a variety of protocols have been
developed to improve and hasten this process [14–17].
Some of these protocols have generated RPE cells from
integration-free iPSCs [61, 62] as these cells are more likely
to be free of mutations due to the reprogramming process,
and are therefore better candidates for transplantation pur-
poses. Here, we have used GMP-compatible conditions to
differentiate RPE from iPSCs that have been generated
using integration-free reprogramming, and demonstrated
that the iPSC-RPE cells possessed key characteristics that
will likely be essential to their function in clinical uses.
Cultures of iPSC-RPE cells have been characterized
with respect to gene expression, the presence of selected
protein markers, and some functional assays [25, 63]. An
extensive recent study focused on ATP-dependent RPE
physiology [64]. The particular focus in the present
study has been on aspects of RPE cell biology that are
critical for retinal health. By week 7 of the differentiation
process, we observed robust expression of signature RPE
proteins, including BEST1, RPE65, and MITF. At that
time, the cytoskeleton of the cells resembled that of an
epithelium, with actin filaments organized at the cortex,
and microtubules arranged horizontally in the apical cell
body and vertically throughout the cell body [40–43]. The
epithelial arrangement of the cytoskeleton was under-
scored by our live-cell imaging analysis, in which 8-week
cultures of iPSC-RPE cells exhibited lateral and vertical
motility of endolysosomes. The observed intracellular mo-
tility is a critical indicator of RPE cell health. Each RPE cell
in the human retina must efficiently degrade phagosomes
derived from 30 POSs on a daily basis [65]. Defects in
motor proteins that drive organelle motility in the RPE
have been shown to compromise phagosome degradation,
and lead to retinal pathology, including symptoms of
AMD, which is potentially the most significant target dis-
ease of RPE transplantation [18, 38].
In addition, the iPSC-RPE cells showed both normal
expression and localization of tight junction proteins, in-
cluding ZO-1, occludin, and claudin19, by week 7 of the
differentiation [66, 67]. This was reflected functionally
by the TER of the cultures, which by week 7 had reached
200Ω.cm2. Finally, by week 8 of the differentiation
process, we observed surface localization of the recep-
tors integrin αvβ5 and MERTK, which participate in the
binding and ingestion of POSs, respectively [31, 32].
These receptors were shown to be functional in assays
that demonstrated the phagocytosis of POSs by iPSC-
RPE cells, with kinetics comparable to that in vivo.
These results support the use of iPSC-RPE cells for in
vitro studies of pathogenicity in RPE disease. In addition,
a clinically relevant goal for RPE cells derived from
iPSCs is to be able to transplant these cells into patients
with maculopathies, where RPE dysfunction or dys-
trophy contributes to the overall pathology. The RPE
can be transplanted as either an intact sheet of cells or
as a suspension of dissociated cells [68, 69]. A major
concern with the suspension method is that the cells
may not integrate properly in order to perform their
function. Here, we demonstrated that a suspension of
iPSC-RPE cells can integrate into the host RPE mono-
layer, and is capable of partially rescuing a critical func-
tion of the RPE that has been compromised due to a
genetic defect. The ability of iPSC-RPE cells to rescue
the pathology associated with certain maculopathies is
likely to be dependent on the quality of the RPE cells
that are used. In this study, we placed a special emphasis
on characterizing the highly sensitive cell biological
characteristics of iPSC-RPE cells, such as intracellular
trafficking, to obtain well differentiated cultures suitable
for transplantation.
Conclusions
We have generated lines of iPSC-RPE cells, using a nonin-
tegrating method of cellular reprogramming and a differ-
entiation protocol, under GMP-compatible conditions.
The iPSC-RPE cells were shown to possess important RPE
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characteristics of normal RPE, including, for the first time,
critical aspects of RPE cell biology. Thus, this report docu-
ments a significant addition to a growing body of litera-
ture, validating the differentiation of bona-fide RPE cells
from stem cells, for both disease-in-a-dish modeling and
therapeutic transplantation.
Additional files
Additional file 1: Is a figure showing (A, B) brightfield micrographs of
iPSC-RPE 1 (A) and iPSC-RPE 3 (B), illustrating the pigmentation and
cobblestone morphology of the cells; (C, D) phalloidin labeling of iPSC-RPE
1 (C) and iPSC-RPE 3 (D), illustrating the cortical arrangement of actin
filaments in the cells; (E–H) Immunofluorescence micrographs, illustrating
expression of the tight junction proteins, ZO-1 (E, F) and occludin (G, H), in
iPSC-RPE 1 and 3. Scale bars: A, B, 60 μm; C–H, 20 μm. (TIF 5893 kb)
Additional file 2: Is a figure showing quantification of phagocytosis in
iPSC-RPE 1 and 3 exposed to porcine POSs for 2 h (pulse), washed
extensively to remove unbound POSs, and then allowed either a 2-h or
5-h chase period to ingest and degrade the POSs. Graph shows the total
number of ROSs quantified from confluent fields of view after the
pulse and the two separate chase periods. Data represent mean ± SD.
(TIF 89 kb)
Additional file 3: Is a figure showing alpha tubulin labeling in iPSC-RPE
1 (A, C, E, G) and iPSC-RPE 3 (B, D, F, H) showing the arrangement of
microtubules in an apical region (A, B), middle region (C, D), and basal
region (E, F) of the cells. The apical region is dominated by horizon-
tally-oriented microtubules whereas the basal region consists mainly of
vertically-oriented microtubules. (G, H) z projections; z planes at the
locations of the yellow lines illustrating the presence of primary cilia
(indicated by white arrowheads) on the apical surface of the iPSC-RPE cells.
Scale bars: 20 μm. (TIF 4278 kb)
Additional file 4: Is a movie showing live-cell imaging of endolysosomes,
labeled with LysoTracker, showing the 4D movement of these organelles in
iPSC-RPE cells cultured on laminin-coated chambered coverglass. The
movie was acquired at 1.9 frames per second using a spinning disk
confocal microscope, and plays at 10 frames per second. Scale bar, 5 μm.
(MP4 727 kb)
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